secwatch.observer — SEC 8-K summary
======================================

Issuer:     Praxis Precision Medicines, Inc. (PRAX)
CIK:        0001689548
Form:       8-K
Filed at:   2023-02-07T23:59:59+00:00
Accession:  0001689548-23-000043
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Praxis reports FY2022 net loss $214M; cash $100.5M, runway into 1Q24
--------------------------------------------------------------------

- Cash and investments $100.5M as of Dec 31, 2022, down from $275.9M; expected to fund ops into 1Q24.
- Net loss FY2022 $214.0M vs $167.1M; Q4 net loss $41.2M.
- R&D expense FY2022 $155.0M, up from $120.3M, reflecting Cerebrum/Solidus platform spending.
- Phase 2b ulixacaltamide topline results for essential tremor expected in 1Q23.
- Entered UCB collaboration for KCNT1 program; up to ~$100M in milestones plus royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689548/000168954823000043/0001689548-23-000043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689548/000168954823000043/prax-20230207.htm
  HTML page:      https://secwatch.observer/filing/0001689548-23-000043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer